All In Biotech

Drug Trial Radar · NCT05167864

Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area

A Randomized Prospective Evaluation of Four Injectable Neuromodulators in the Glabella Area

Last checked: Nov 20, 2026Latest source record: Jan 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 143 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

143

Actual

Start

Mar 4, 2022

Primary completion

Jun 30, 2023

Study completion Jun 30, 2023

Sponsor

Lead sponsor
University of PennsylvaniaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 30 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to use 3D imaging to evaluate the effects of four FDA approved neuromodulators on facial lines, wrinkles and animation. Participation is available to women who have never had a cosmetic procedure above the malar region nor a treatment with a neuromodulator within 12 months. All subjects will undergo 3D imaging using the VECTRA M3 (Canfield Scientific, Inc, Fairfield, NJ) prior to treatment with a neuromodulator in order to determine their baseline dimensions. Imaging will be repeated post injection to determine change over time.

Conditions

  • Cosmetic Techniques

Interventions

  • Onabotulinumtoxina for InjectionDrug

    cosmetic injection into the glabella area (eyebrow area)

  • Abobotulinumtoxina for InjectionDrug

    cosmetic injection into the glabella area (eyebrow area)

  • IncobotulinumtoxinA for InjectionDrug

    cosmetic injection into the glabella area (eyebrow area)

  • PrabotulinumtoxinA for InjectionDrug

    cosmetic injection into the glabella area (eyebrow area)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the Change in Dynamic Strain in the Glabella Area After Injection Over TimeTime frame: day 3, day 30, day 90, day 180

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Penn Medicine

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.